Although these therapies are effective for many cancer patients, complete response rate ranges from around 20% for anti-CTLA-4 antibody therapy42,43 to 30% for anti-PD/anti-PD-L1 therapy in the case of melanoma41,43. This evidence concerns the gene CTLA4 and cancer.